BioNTech (NASDAQ:BNTX) CEO Sells $2,300,640.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $95.86, for a total value of $2,300,640.00. Following the completion of the transaction, the chief executive officer owned 63,209 shares in the company, valued at $6,059,214.74. This represents a 27.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, October 9th, Ugur Sahin sold 36,209 shares of BioNTech stock. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33.
• On Thursday, October 8th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $92.31, for a total transaction of $2,492,370.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The stock was sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.

BioNTech Stock Up 5.3%

Shares of NASDAQ:BNTX opened at $96.96 on Friday. The firm has a 50 day simple moving average of $99.17 and a 200-day simple moving average of $95.17. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the previous year, the business posted ($1.60) EPS. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
• Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
• Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
• Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
• Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BNTX shares. Citigroup reduced their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Berenberg Bank set a $140.00 target price on BioNTech in a research report on Wednesday, September 16th. Canaccord Genuity Group lowered their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a report on Monday, August 31st. Morgan Stanley reduced their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Flossbach Von Storch SE bought a new stake in shares of BioNTech in the 2nd quarter valued at $207,142,000. Bank of America Corp DE raised its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares in the last quarter. First Trust Advisors LP raised its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of BioNTech during the 2nd quarter worth about $39,385,000. Finally, SEB Asset Management AB acquired a new stake in shares of BioNTech during the first quarter worth $17,804,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.